New Drug-Eluting Balloon Matches Standard Stents in Safety and Effectiveness: SELUTION4ISR Trial
A new drug-eluting balloon (DEB) may offer a safer and equally effective alternative to conventional metallic stents for patients with coronary in-stent restenosis (ISR), according to the SELUTION4ISR Trial.
The findings, presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference in San Francisco, mark a major advancement in interventional cardiology.
The study was led by researchers at Mount Sinai Hospital, New York.
No direct quote available in the text.
Dr. Kamal Kant Kohli, a chest specialist with over 30 years of practice, is the Chief Editor of Medical News at Medical Dialogues.
Author's summary: New DEB offers safer alternative to metallic stents.
More News
- In the Maldives, Luxury Takes Many Shapes
- European Parliament weighs banning Russian media from its networks
- The Grateful Dead: 50 for 50 (at 60)
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- Gmail Data Breach: 183 million accounts exposed in massive leak
- How to Set Up TikTok Shop for Small Businesses Safely
- NBCU, iHeartMedia Agree On 2026 Winter Olympics Partnership | Radio & Television Business Report
- Allied Nations Deploy $11.5B to Rebuild Critical Minerals Supply Chains
- NVIDIA Stock Soars 3.6% as Company Edges Closer to $5 Trillion Valuation
- Etsy Stock Falls 9% As CEO Steps Down